📣 VC round data is live. Check it out!
- Public Comps
- Passage Bio
Passage Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Passage Bio and similar public comparables like Jupiter Neurosciences, Alligator Bioscience, NFL Biosciences, Pharma Equity Group and more.
Passage Bio Overview
About Passage Bio
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Founded
2017
HQ

Employees
60
Website
Financials (LTM)
Market Cap
$15M
Valuation Multiples
Start free trialPassage Bio Financials
Passage Bio reported last 12-month revenue of —.
In the same LTM period, Passage Bio generated — in gross profit and had net loss of ($43M).
Revenue (LTM)
Passage Bio P&L
In the most recent fiscal year, Passage Bio reported revenue of — and EBITDA of ($42M).
Passage Bio is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.
Financial data powered by Morningstar, Inc.
Passage Bio Stock Performance
Passage Bio has current market cap of $15M.
Market Cap Evolution
Passage Bio's stock price is $4.61.
Passage Bio share price decreased by 9.7% in the last 30 days, and by 47.1% in the last year.
Passage Bio has an EPS (earnings per share) of $-14.19.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $15M | -7.2% | -9.7% | -49.0% | -47.1% | $-14.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPassage Bio Valuation Multiples
Passage Bio trades at 0.2x EV/EBITDA.
Passage Bio Financial Valuation Multiples
As of May 5, 2026, Passage Bio has market cap of $15M.
Passage Bio has a P/E ratio of (0.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Passage Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Passage Bio Margins & Growth Rates
Passage Bio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Passage Bio Operational KPIs
Passage Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Passage Bio Competitors
Passage Bio competitors include Jupiter Neurosciences, Alligator Bioscience, NFL Biosciences, Pharma Equity Group, Argenica Therapeutics, Poxel, Abera Bioscience, Diamyd Medical, NextCell Pharma and Celyad Oncology.
Most Passage Bio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 741.0x | — | (1.9x) | — | |||
| 222.0x | — | (22.3x) | (1.3x) | |||
| — | — | (3.0x) | (2.9x) | |||
| — | — | (4.5x) | — | |||
| — | 0.7x | — | 0.9x | |||
| 3.9x | — | (2.1x) | — | |||
| — | — | (12.1x) | — | |||
| 364.3x | — | (0.3x) | (0.3x) | |||
This data is available for Pro users. Sign up to see all Passage Bio competitors and their valuation data. Start Free Trial | ||||||
Passage Bio Funding History
Before going public, Passage Bio raised $226M in total equity funding, across 2 rounds.
Passage Bio Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Passage Bio
| When was Passage Bio founded? | Passage Bio was founded in 2017. |
| Where is Passage Bio headquartered? | Passage Bio is headquartered in United States. |
| How many employees does Passage Bio have? | As of today, Passage Bio has over 60 employees. |
| Who is the CEO of Passage Bio? | Passage Bio's CEO is William Chou. |
| Is Passage Bio publicly listed? | Yes, Passage Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Passage Bio? | Passage Bio trades under PASG ticker. |
| When did Passage Bio go public? | Passage Bio went public in 2020. |
| Who are competitors of Passage Bio? | Passage Bio main competitors include Jupiter Neurosciences, Alligator Bioscience, NFL Biosciences, Pharma Equity Group, Argenica Therapeutics, Poxel, Abera Bioscience, Diamyd Medical, NextCell Pharma, Celyad Oncology. |
| What is the current market cap of Passage Bio? | Passage Bio's current market cap is $15M. |
| Is Passage Bio profitable? | No, Passage Bio is not profitable. |
| What is the current net income of Passage Bio? | Passage Bio's last 12 months net income is ($43M). |
| How many companies Passage Bio has acquired to date? | Passage Bio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Passage Bio has invested to date? | Passage Bio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Passage Bio
Lists including Passage Bio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.